Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid interest in cancer research owing to their profound antitumoral activity. The lead compound of the imidazoquinoline family, imiquimod, is marketed as a topical formulation. It is efficacious against many primary skin tumors and cutaneous metastases. Using different imidazoquinoline species, distinct functions of TLR7 and TLR8 have been discovered. The predominant antitumoral mode of action of these agents is TLR7/ 8-mediated activation of the central transcription factor nuclear factor-jB, which leads to induction of proinflammatory cytokines and other mediators. Cutaneous dendritic cells are the primary responsive cell type and initiate a strong Th1-weighted antitumoral cellular immune response. Recent research has shown that dendritic cells themselves acquire direct antitumoral activity upon stimulation by imiquimod. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of TLR7/8. The proinflammatory activity of imiquimod, but not resiquimod, appears to be augmented by suppression of a regulatory mechanism, which normally limits inflammatory responses. This is achieved independently of TLR7/8 through interference with adenosine receptor signaling pathways. Finally, at higher concentrations imiquimod exerts Bcl-2-and caspase-dependent proapoptotic activity against tumor cells.
Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid interest in cancer research owing to their profound antitumoral activity. The lead compound of the imidazoquinoline family, imiquimod, is marketed as a topical formulation. It is efficacious against many primary skin tumors and cutaneous metastases. Using different imidazoquinoline species, distinct functions of TLR7 and TLR8 have been discovered. The predominant antitumoral mode of action of these agents is TLR7/ 8-mediated activation of the central transcription factor nuclear factor-jB, which leads to induction of proinflammatory cytokines and other mediators. Cutaneous dendritic cells are the primary responsive cell type and initiate a strong Th1-weighted antitumoral cellular immune response. Recent research has shown that dendritic cells themselves acquire direct antitumoral activity upon stimulation by imiquimod. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of TLR7/8. The proinflammatory activity of imiquimod, but not resiquimod, appears to be augmented by suppression of a regulatory mechanism, which normally limits inflammatory responses. This is achieved independently of TLR7/8 through interference with adenosine receptor signaling pathways. Finally, at higher concentrations imiquimod exerts Bcl-2-and caspase-dependent proapoptotic activity against tumor cells. Oncogene (2008) 27, 190-199; doi:10.1038/sj.onc.1210913 Keywords: TLR7; TLR8; skin cancer; imiquimod; imidazoquinolines; cancer immunity TLR7, TLR8 and small-molecule agonists TLR7 and TLR8 functions Toll-like receptor 7 (TLR7) and TLR8 are phylogenetically and structurally closely related members of the TLR family; together with TLR9 they constitute one of the six major TLR clades (Roach et al., 2005) . With the exception of a small proportion of TLR8 which is expressed at the cell surface, both TLR7 and TLR8 are localized intracellularly to endosomal membranes, similar to TLR3 and TLR9 (Lee et al., 2003; Nishiya and DeFranco, 2004; Miggin and O'Neill, 2006) . These four intracellular receptors represent a group of so-called antiviral TLRs. However, the molecular mechanisms guiding endosomal localization of TLR3 and TLR7 appear to be distinct inasmuch as TLR3 is targeted intracellularly by a sequence of 23 amino acids within the linker region between the TIR domain and the transmembrane domain, while TLR7 localizes intracellularly via its transmembrane domain (Nishiya et al., 2005) . Both TLR7 and TLR8 have been identified as natural receptors for single-stranded RNA, and they are thought to act as potent activators of innate immune responses upon viral infections. Sequence specificities of TLR7 and TLR8 have not been conclusively defined yet, but ssRNA sequences containing GU-rich or poly-U sequences can stimulate both receptors (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004) . In addition, siRNA sequences containing an internal 5 0 -UGUGU-3 0 motif appear to bind to TLR7/8 (Judge et al., 2005) . Certain siRNA sequences may even stimulate TLR7/8 independently of their GU content suggesting specific sequences recognized by TLR7/8 (Hornung et al., 2005) . The level of nucleoside modification appears to be a discriminating feature for TLR7 and TLR8 to distinguish between viral and mammalian ssRNA (Kariko et al., 2005) .
The scientific and clinical interest in TLR7 and TLR8 for cancer biology has originated from the antitumoral activity of some small-molecule compounds (Sidky et al., 1992) which have later been shown to act as agonists at one or both receptors (Hemmi et al., 2002; Jurk et al., 2002) . Indeed, together with the study of genetically engineered mice (MyD88 or TLR deficient) (Gibson et al., 2002; Hemmi et al., 2002) many functions of TLR7 and TLR8 have been unraveled primarily through studies of the mode of action of such small molecule compounds, imidazoquinolines in particular (Gorden et al., 2005; Jurk et al., 2006; Gorden et al., 2006b; Ma et al., 2007) . The intracellular localization of TLR7 and TLR8 usually necessitates cellular uptake of drugs targeting these receptors.
Small-molecule agonists at TLR7 and TLR8 Imiquimod (R837; 1-(2-methylpropyl)-1H-imidazo [4, 5-c] quinolin-4-amine), is a nucleoside analogue with a molecular mass of M r ¼ 240.3. It is the lead compound of the imidazoquinoline family and has been studied most extensively. Most of the findings concerning the antitumoral mode of action of TLR7/8 agonists, clinical efficacy and safety reviewed here have been obtained with imiquimod (Scho¨n and Scho¨n, 2007) . Imiquimod activates preferentially TLR7; its agonistic activity at TLR8 appears to be much weaker (Lee et al., 2003) .
Resiquimod (R848; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), M r ¼ 314.4) is a selective ligand for TLR7 in the murine and for TLR7 and TLR8 in the human system. Resiquimod induces more pronounced cytokine secretion, macrophage activation and enhancement of cellular immunity as compared to imiquimod (Wagner et al., 1997 (Wagner et al., , 1999 Imbertson et al., 1998; Bernstein et al., 2000; Burns et al., 2000) .
Gardiquimod (1-(4-amino-2-ethylaminomethylimidazo-[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol; M r ¼ 313.4) is another imidazoquinoline derivative that, similar to imiquimod, induces activation of nuclear factor (NF)-kB in cells expressing human or murine TLR7. However, based on data derived from HEK293 cells expressing human or mouse TLR7 gardiquimod is approximately ten times more potent as compared to imiquimod. At high concentrations (that is, X3 mg ml À1 ), gardiquimod also activates TLR8.
Another commercially available compound with the thiozoloquinolone backbone structure is CL075 (3M-002), a compound of M r ¼ 243.3 that preferentially stimulates TLR8 in human PBMC. It has been demonstrated recently that CL075 induces secretion of TNFa and IL-12 by human PBMC through agonistic activity at TLR8. In addition, although to a markedly lesser extent, the compound activates TLR7. Based upon studies using transfected HEK293 cells, concentrations of CL075 required for activation of TLR7 are approximately 10-fold higher than those needed for TLR8 stimulation. In contrast to CL075, CL097 (M r ¼ 242.3) predominantly activates TLR7. Again using transfected HEK293 cells it was found that CL097 induces TLR7-mediated activation of NF-kB at concentrations of 0.1 mg ml À1 , while 1.0mg ml À1 are required to induce NF-kB activation in a TLR8-dependent fashion (Gorden et al., 2005; Gorski et al., 2006; Levy et al., 2006; Qin et al., 2006; Wille-Reece et al., 2006) .
The L-nucleoside loxoribine (M r ¼ 339.3) is a guanosine analog derivatized at positions C8 and N7. This compound does not share the basic imidazoquinoline structure with the aforementioned agents. The activation of the innate immune system through loxoribine is, similarly to imiquimod, largely restricted to TLR7 (Pope et al., 1995; Heil et al., 2003; Lee et al., 2003) .
The delineated small-molecule agonists at TLR7 and TLR8 are schematically summarized in Figure 1 .
Dissecting functions of TLR7 and TLR8 by small-molecule agonists Following the discovery that imiquimod and resiquimod somewhat differentially activate TLR7 and TLR8 signaling, respectively (Hemmi et al., 2002; Jurk et al., 2002) , several other compounds of the imidazoquinoline family have been studied regarding their activity at both receptors. Indeed, these recent studies have been instrumental for dissecting distinct cytokine induction profiles and other functions of both receptors (Gorden et al., 2005 (Gorden et al., , 2006a Gorski et al., 2006; Jurk et al., 2006) .
In the first study of that kind it was found that the specific TLR7 agonist (3M-001, (N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl-]methanesulfonamide) primarily activated plasmacytoid dendritic cells, B cells and monocytes, while a TLR8 agonist (3M-002, CL075; 2-propylthiazolo[4,5-c]quinolin-4-amine) induced cytokine production by myeloid dendritic cells, monocytes and monocyte-derived dendritic cells (Gorden et al., 2005) . Accordingly, the TLR7 agonist preferentially induced secretion of IFNa and IFN-regulated chemokines, such as I-TAC (CXCL11) and IP-10 (CXCL10), while the TLR8 agonist predominantly induced proinflammatory cytokines and chemokines including TNFa, IL-12 and MIP-1a (CCL3) (Gorden et al., 2005) . These observations are consistent with the known activities of imiquimod, which also acts predominantly as activator of TLR7 (Gibson et al., 2002) , and indicated differential target cell selectivity of TLR7 and TLR8 agonists as well as distinct cytokine induction profiles of the two receptors (Gorden et al., 2005) . The activity of imidazoquinoline agonists at TLR7 and TLR8, respectively, can be modulated by modified oligodeoxynucleotides. Interestingly, such treatments inhibit TLR7 while they enhance TLR8 signaling induced by the respective agonists (Jurk et al., 2006; Gorden et al., 2006b ). In addition, the functionality of murine TLR8 has first been demonstrated by using a small-molecule TLR8 agonist (3M-002) together with polyT oligodeoxynucleotides (Gorden et al., 2006a) . Of particular relevance for antitumoral immune responses is the differential triggering of NK cell activity by imidazoquinolines inasmuch as TLR8 agonists showed more pronounced indirect NK cell activation as compared to TLR7 agonists (Gorski et al., 2006) . However, direct interaction of any of the compounds with TLRs has not been demonstrated (yet).
Cellular events induced by small-molecule agonists at TLR7/8
Modulation of inflammatory mediators by imiquimod and related compounds Already the first scientific investigations into the mode of action of imiquimod and numerous studies since have demonstrated that the compound stimulates the production and secretion of proinflammatory cytokines, which then induce a profound tumor-directed cellular immune response (Reiter et al., 1994; Stanley, 2002) . Given that dendritic cells produce inflammatory cytokines in response to markedly lower concentrations of imiquimod as compared to other cells, they are the primary responsive cell type (Reiter et al., 1994; Gibson et al., 1995 Gibson et al., , 2002 Megyeri et al., 1995) . In most experimental studies in vitro, imiquimod concentrations of up to 5 mg ml À1 elicited a robust proinflammatory response by dendritic cells. A number of additional imidazoquinolines (some have been mentioned above) have been tested in vitro for their capacity to induce cytokine and chemokine production, and for some species effective concentrations of as low as 0.05 mg ml À1 have been described (Gerster et al., 2005) . In addition, it has been shown in vivo that topically applied imiquimod induces functional maturation of epidermal Langerhans cells and stimulates migration of these antigen-presenting cells to regional lymph nodes where they presumably promote a specific T-cell response (Stanley, 2002) .
Stimulation of TLR7-or TLR8-mediated signaling pathways through imiquimod or other imidazoquinolines results in the activation of central transcription factors, NF-kB (nuclear factor-kappa B) in particular. Under resting conditions, the (hetero)-dimeric NF-kB is kept inactive within the cytoplasm through binding to the inhibitory factor, IkB. Following receptor-mediated stimulation, IkB is phosphorylated through the IKK complex. This phosphorylation results in release, activation and nuclear translocation of NF-kB, where it induces transcription of a multitude of genes, including those of cytokines, chemokines, adhesion molecules and apoptosisrelated proteins (Karin, 2006) . As demonstrated in large gene expression array analyses, topical treatment of Figure 1 Agonistic activity of small-molecule compounds at Toll-like receptor 7 (TLR7) and/or TLR8. Thickness of arrows corresponds to preferential activity. Imiquimod activated TLR7 in the murine and TLR7 and TLR8 in the human system.
TLR7 and TLR8 as targets in cancer therapy
MP Schön and M Schön cutaneous tumors or virally induced skin lesions with imiquimod results in markedly elevated expression of numerous gene products involved in the regulation of innate immune functions (Buates and Matlashewski, 2001; Dummer et al., 2003a) . To name but a few, imiquimod induces expression of proinflammatory cytokines including IFNa, TNFa, IL-2, -6, -8, -12, G-CSF and GM-CSF, as well as chemokines such as CCL3 (MIP-1a), CCL4 (MIP-1b) and CCL2 (MCP-1) (Reiter et al., 1994; Weeks and Gibson, 1994; Gibson et al., 1995; Megyeri et al., 1995; Wagner et al., 1997) . In addition to the NF-kBmediated transcription of proinflammatory mediators, it appears that TLR-7-(and TLR-8)-agonistic activities of imiquimod induce some proinflammatory cytokines, such as IFNg, in a NF-kB-independent fashion. The known functions of these mediators explain, at least in part, many cellular responses to imiquimod including activation and application-site-directed migration of dendritic cells and their precursors as well as attraction and stimulation of cytotoxic T-lymphocytes and other immune cells. Along this line, it has been demonstrated that plasmacytoid dendritic cells accumulate in subcutaneous melanoma metastases in a mouse model (Palamara et al., 2004) and that plasmacytoid predendritic cells migrate into the skin (Urosevic et al., 2005) following application of imiquimod. The net result of the imiquimod-induced cytokine production is a Th1-weighted cellular immune response, while Th2 signaling pathways appear to be suppressed. The latter activity is exemplified by IFNg-dependent downregulation of IgE-synthesis by resiquimod (Frotscher et al., 2002) . Other indirect biological effects that can be explained by the TLR-dependent activation of NF-kB by imiquimod and subsequent expression of IFNa, IL-1 and other mediators include enhanced expression of the opioid growth factor receptor on tumor cells and cells of the inflammatory infiltrate (Urosevic et al., 2004) as well as changes in the epidermal barrier function (Barland et al., 2004) .
Cellular immune reactions induced by imidazoquinolines
Strong tumor-directed cellular immune responses have been observed in most skin tumors treated topically with imiquimod . These results are consistent with and in support of observations that imiquimod strongly augmented the mounting of a cellular immune response in cutaneous vaccinations with nontumoral antigens (Lore et al., 2003; Thomsen et al., 2004; Zuber et al., 2004) , thus employing the same principle as other adjuvants which utilize TLR-dependent signaling cascades in order to enhance activation of cytotoxic T cells (Schwarz et al., 2003) . Imiquimodenhanced activation and immigration of cytotoxic T cells has been observed in vaccination studies with melanoma antigens (Shackleton et al., 2004) . Moreover, recent in vivo data have demonstrated that imiquimod strongly enhances antigen-specific activation of antitumoral T cells (Rechtsteiner et al., 2005; Prins et al., 2006) and augments protective cellular antitumoral immunity against melanoma cells following vaccination with Listeria (Craft et al., 2005) . As a conspicuous clinical indication for a direct melanocyte-directed immune reaction, localized vitiligo (depigmentation due to an autoimmune reaction against melanocytes) was observed. Another TLR-dependent immunomodulatory effect of imiquimod is the induction of 2 0 5 0 -oligoadenylsynthase, which is associated with stimulation of NK (natural killer) cells, immunocytes that are pivotally involved in antiviral and antitumoral immune responses (Navi and Huntley, 2004) . However, compounds activating preferentially TLR8 may even prove superior with regard to NK cell activation (Gorski et al., 2006) . Given that imiquimod has been shown to induce perforin in cytotoxic T cells under experimental conditions in vitro (Ambach et al., 2004) it is conceivable that imiquimod exerts even broader (pleiotropic) stimulatory effects on T cells and other immune cells.
Based upon the activation of dendritic cells through imiquimod, it has been hypothesized that the compound elicits an indirect vaccination effect, thus leading to prolonged Th1-weighted immune responses against tumors and virally infected cells (Harrison et al., 1994; Bernstein et al., 1995; Burns et al., 2000; Suzuki et al., 2000) . However, untreated tumors in the vicinity of tumors that responded well to imiquimod did not show signs of inflammation or regression, and experimental evidence to support this intriguing hypothesis has not been published yet.
In addition to the indirect stimulation of lymphocytes and NK cells via activation of dendritic cells, a recent study has demonstrated elegantly that imiquimodtreated dendritic cells themselves presumably acquire direct antitumoral functions in vivo (Stary et al., 2007) . In this study, peritumoral myeloid dendritic cells in the vicinity of imiquimod-treated basal cell carcinomas expressed perforin and granzyme B, and tumor-infiltrating plasmacytoid dendritic cells expressed TRAIL. In vitro, stimulation of myeloid dendritic cells by imiquimod led to lysis of MHC class I lo tumor cells by these cells, and plasmacytoid dendritic cells acquired the ability to induce apoptosis in Jurkat cells through TRAIL signaling (Stary et al., 2007) . It is conceivable that this novel dendritic cell-based antitumoral mechanism contributes to the apoptosis of imiquimod-treated tumors described earlier (Scho¨n et al., 2003) .
Overall, although some aspects of the TLR-dependent activity of imiquimod and related compounds are not entirely clear yet, there is compelling evidence for the notion that imiquimod-through stimulation of antitumoral T cells following activation of antigen presenting cells as well as through direct antitumoral activation of dendritic cell subsets-exerts its activity primarily at the interface between innate and acquired immunity (Hurwitz et al., 2003; Urosevic et al., 2003) .
Antitumoral efficacy of TLR7/8 agonists in clinical trials
Imidazoquinolines were originally developed in order to generate antiviral agents. Although these substances did not exert direct antiviral activities, some of them showed considerable indirect efficacy against virally induced lesions through TLR7/8-mediated induction of cytokines (Chen et al., 1988; Harrison et al., 1988; Gerster et al., 2005) . Following the demonstration of profound antitumoral activities in preclinical models (Sidky et al., 1992) , imidazoquinolines, the lead compound imiquimod in particular, have moved into the limelight of clinical and experimental oncology. The small size of imiquimod, its hydrophobicity and ability to penetrate the epidermal barrier on the one hand, and, on the other hand, considerable unwanted side effects when the compound is applied systemically, led to the development of a topical formulation (Aldara 5% cream) for the treatment of viral lesions (HPV papillomas) and malignant tumors of the skin. Imiquimod was first approved for the treatment of genital warts and is usually well tolerated (Gollnick et al., 2001) . In addition, several controlled clinical trials as well as many smaller series of cases and case reports have demonstrated that imiquimod is also effective against a variety of primary skin cancers as well as cutaneous metastases of some malignancies. Cutaneous tumors that have responded well to topical treatment with imiquimod include basal cell carcinomas (Sterry et al., 2002; BathHextall et al., 2004; Geisse et al., 2004; Gollnick et al., 2005; Schulze et al., 2005) , keratoacanthomas (Dendorfer et al., 2003; Peris et al., 2003) , actinic keratoses (Stockfleth et al., 2001 (Stockfleth et al., , 2002 Lebwohl et al., 2004; Szeimies et al., 2004; Korman et al., 2005 ) and Bowen's disease (the latter two entities represent epidermal carcinoma in situ) (Patel et al., 2006; Peris et al., 2006) , cutaneous metastases of melanoma (Steinmann et al., 2000; Bong et al., 2002; Ugurel et al., 2002; Wolf et al., 2003; Zeitouni et al., 2005) , some cases of primary melanoma in situ (Fleming et al., 2004; Kamin et al., 2005; Ray et al., 2005; Wolf et al., 2005; Lonsdale-Eccles et al., 2006) and cutaneous T-cell lymphomas (Suchin et al., 2002; Dummer et al., 2003b; Chong et al., 2004; Deeths et al., 2005) . Clinical responses of cutaneous neoplasias to topical treatment with imiquimod have also been observed in difficult-to-treat patient populations, such as organ transplant patients under immunosuppressive therapy (Smith et al., 2001; Prinz et al., 2004; Brown et al., 2005) or Xeroderma pigmentosum patients suffering from rapid development of multiple UV-induced cutaneous malignancies (Giannotti et al., 2003; Roseeuw, 2003) . A recent meta-analysis of five randomized, double blind clinical trials showed that approximately 50% of imiquimod-treated patients with actinic keratoses were cleared of their lesions, as compared to only 5% in the vehicle-treated group (Hadley et al., 2006) . Other imidazoquinolines, resiquimod in particular, have also been assessed in preclinical and early clinical trials (Miller et al., 2002; Sauder et al., 2003) .
Off-target effects of imiquimod
Other activities influencing immunological effects Although imiquimod induces primarily a Th1-dominated cellular immune response under most clinical and experimental circumstances, this rule has some remarkable exceptions which cannot be explained easily by TLR7-or TLR8-dependent mechanisms and whose molecular basis is not entirely clear yet.
Under experimental conditions, there is some evidence suggesting that imiquimod can enhance antibody production by B cells (Hengge and Ruzicka, 2004) , a function that is typically governed through a Th2-dominated microenvironment. It appears that imiquimod and related compounds exert a direct stimulatory effect on antibody production inasmuch as they mimic CD40-dependent signals, which are normally sent by T cells (Bishop et al., 2001) . In addition, imidazoquinolines can stimulate the proliferation of cultured B cells, even in the absence of other immunocytes, although the increase in B-cell proliferation was more pronounced when preactivated cultures were exposed to imiquimod . However, resiquimod suppressed IgE production in an IFNg-dependent fashion (Frotscher et al., 2002) , an activity that needs to be reconciled with the putative CD40-mimicking activity in future studies.
Recent research has demonstrated that imiquimod can activate NF-kB and increase expression of some proinflammatory cytokines (IL-6, IL-8, TNFa and IL1b) in TLR-7-and TLR-8-negative cell lines (Scho¨n et al., 2006) . In addition, imiquimod increased IL-1b mRNA in mononuclear cells from mice deficient for MyD88 (myeloid differentiation factor 88, an adaptor molecule essential for TLR-mediated signaling), albeit at lower levels than in the counterpart cells from wildtype mice. Competitive radioligand binding studies have shown that imiquimod binds to adenosine receptors with highest affinity at the A 2A receptor (K i -value 2.16 mM), followed by the A 1 receptor (K i -value 2.94 mM) where it presumably acts as a partial antagonist. In addition, a moderate but consistent receptorindependent inhibition on adenylyl cyclase activity was observed. Activity of resiquimod at adenosine receptors could not be detected, however. Given that adenosine receptor-mediated signaling pathways can suppress transcription of proinflammatory cytokines (Odashima et al., 2005) , it is conceivable that imiquimod interferes with a negative feedback mechanism that normally contains inflammatory reactions. The net result of this additional activity of imiquimod would be an augmentation of inflammation synergistically to the TLRmediated proinflammatory activity (Scho¨n et al., 2006) .
Proapoptotic activity of imiquimod
In addition to its predominant activation of NF-kB, imiquimod modulates STAT-1 (signal transducer and activator of transcription-1) signaling pathways (Dockrell and Kinghorn, 2001 ). This interaction may contribute to the transcription of proinflammatory cytokines (Bottrell et al., 1999) , but also to the induction of apoptosis in various cell types (Stephanou and Latchman, 2005) . In addition, imiquimod led to increased expression of the death receptor CD95 and to decreased expression of the antiapoptotic protein Bcl-2 (Vidal et al., 2004) in some basal cell carcinomas in vivo. Thus, it is conceivable that imiquimod enhances susceptibility of tumor cells to apoptotic stimuli, for example, to CD95L, TRAIL or other death ligands, which can be produced by neighboring tumor cells, infiltrating lymphocytes or dendritic cells (Stary et al., 2007) . This proapoptotic activity of imiquimod could be mediated by TLRdependent regulation of the respective apoptosis-related proteins; it would thus be indirect.
However, imiquimod exerts an additional direct proapoptotic activity against tumor cells (Scho¨n et al., 2003) , a surprising observation that was confirmed in vivo in tumors of different origin (Sidbury et al., 2003; Sullivan et al., 2003; Scho¨n et al., 2004; Vidal et al., 2004) as well as on the cellular level in vitro (Meyer et al., 2003) . While the proapoptotic activity of imiquimod is independent of membrane-bound death receptors, shifts of Bcl-2 proteins in favor of the proapoptotic Bax were observed. Bcl-2 overexpression rendered tumor cells resistant against imiquimod-induced apoptosis (Scho¨n et al., 2003 . In addition, imiquimod-induced direct apoptosis of tumor cells could be abrogated by inhibition of caspase activation. The proapoptotic activity of resiquimod was markedly less pronounced as compared to imiquimod (Scho¨n et al., 2003) . Imiquimod-induced apoptosis occurred (cell type-dependent) at rather high concentrations of approximately 25-50 mg ml À1 , that is, five-to ten-fold higher than those required for TLR-mediated cytokine induction in dendritic cells. However, these concentrations are approximately 3 logs below the marketed formulation (Aldara 5% cream). Thus, it is reasonable to assume that the proapoptotic activity contributes to the overall antitumoral effect of imiquimod in vivo. Indeed, in both basal cell carcinomas (Scho¨n et al., 2003; Vidal et al., 2004) and cutaneous melanoma metastases treated with imiquimod, an increased number of apoptotic cells was detected as compared to the respective controls. However, it appears likely that in vivo additional factors, for example, infiltrating immune cells (Stary et al., 2007) , contribute to the induction of apoptosis in imiquimod-treated tumors. The exact contribution of apoptosis induction to the overall antitumoral activity of imiquimod (and possibly other TLR7/8 agonists) is not entirely clear at this time. The in vivo situation is certainly complex and comprises various levels of interaction between multiple players that are affected directly or indirectly by imiquimod (and presumably other TLR7/8 agonists).
Overall, the predominant antitumoral activity of imidazoquinolines is induction of proinflammatory cytokines achieved through agonistic activity at TLR-7-and TLR-8-mediated signaling cascades, and consecutively, activation of NF-kB. This activity stimulates the production of proinflammatory cytokines and chemokines resulting in a profound Th1-weighted antitumoral cellular immune response and direct antitumoral capacities of dendritic cells. Several secondary effects can also be explained through the TLR7/ 8-dependent activation of NF-kB. In addition, offtarget activities of imiquimod (and presumably other compounds) include interference with adenosine receptor signaling pathways and direct proapoptotic activity against tumor cells.
